Medical Device Regulatory Clarity

Early regulatory choices materially influence development timelines, investment risk, time to market, and long-term flexibility. Our work focuses on defining viable regulatory paths and making the associated risks and tradeoffs explicit for decision-makers.

Strategy Across Technologies & Categories

Regulatory Strategy | Pathway Assessment

Medical device regulatory strategy requires balancing near‑term development decisions with long‑term business and regulatory consequences. Accordingly, our work focuses on identifying and structuring viable regulatory paths, and clarifying the tradeoffs and risks associated with each option. This includes:

Integrated strategy development that considers both near- and long-term plans
Evaluation of regulatory pathways in light of business objectives and constraints
Assessment of prior agency interactions and the likely submission route
Developing a working understanding of the device technology and its use to inform preliminary classification and prior art, including predicates and reference devices that may support safety and effectiveness
Strategic assessment of whether and when to engage the FDA through Q‑Submissions (Q‑Sub, Pre-Sub)
Identification and framing of device-specific risks and regulatory tradeoffs to support informed decision-making
As part of pathway assessment, evaluation of administrative and classification routes, including 513(g) requests where appropriate
Application of relevant agency guidance and consideration of current FDA thinking, specific to the device’s technology and intended use
Early identification of data expectations and potential evidentiary gaps that may affect feasibility, timing, and cost

Agency Engagement & Submissions | Pathway Planning

Once a regulatory direction is defined, attention shifts to execution and agency interaction, while continuing to reassess assumptions, risks, and positioning as new information emerges. In practice, this involves disciplined planning and proportionate engagement aligned with the chosen regulatory strategy.

Continuation of pathway planning, determining first steps and submission routes, including 510(k), De Novo, and PMA as appropriate
Regulatory authority engagement, including meeting strategy, agenda development, formal correspondence, and issue resolution
Principled application of the FDA’s Least Burdensome Approach to support reasoned, proportionate agency requests
Targeted review and refinement of technical documentation, test report elements, and device labeling to support submission readiness
Strategic preparation for and interpretation of agency feedback, including adjustment of development activities or submission strategy where warranted

Additional Regulatory Advisory

Depending on device type, development stage, and organizational needs, targeted regulatory advisory may be appropriate to complement the broader strategy and execution.

Design control considerations before and after submission
Risk management development for device classification and clinical study planning, including IDE risk determination
Human factors and usability considerations aligned with FDA guidance and ISO/IEC 62366, as applicable
Advisory for software as a medical device or integral to a device, including artificial intelligence (AI)
Establishment registration (foreign and domestic) and product/device listing
Support for regulatory inspections, audits, and related agency reviews
Quality management system readiness assessment, e.g. FDA Quality Management System Regulation (QMSR)/ Current Good Manufacturing Practices (cGMP) and ISO 13485 Medical Device Quality Management (QMS)
Regulatory considerations in manufacturing strategy and supplier qualification and selection, including QMS readiness
Targeted advisory on regulatory risk exposure during investment, partnering, or acquisition activities
Other regulatory advisory discussions relevant to the device, organization, and company goals

Investor‑Side Regulatory & Quality Due Diligence

Investment and acquisition decisions involving medical devices often hinge on regulatory and quality assumptions that are difficult to fully validate from deal materials alone. Our investor‑side diligence work focuses on independently assessing regulatory soundness, quality system maturity, and manufacturing readiness to surface risk early—before commitments are made.

We work directly on behalf of investors, acquirers, and corporate development teams to evaluate whether a company’s regulatory positioning, development plans, and operational foundations are credible, defensible, and aligned with current regulatory expectations. This includes identifying misalignment between stated strategy and regulatory reality, areas of unrecognized risk, and decision points that could materially affect valuation, timing, or long‑term flexibility.

Our diligence engagements are judgment‑driven and senior‑led, drawing on deep regulatory, quality, and manufacturing experience. The objective is to provide investors with clear, independent insight that supports informed investment, partnership, or acquisition decisions.

Typical diligence focus areas include:

Regulatory pathway credibility and underlying assumptions
Classification and submission strategy risk
Quality system maturity and inspection readiness
Manufacturing and supplier regulatory readiness
Human factors, clinical, and post‑market considerations with downstream impact
Alignment between regulatory claims, documentation, and operational reality

Meeting Your Stakeholder's Needs

Our advisory supports medical device companies by aligning regulatory strategy with business objectives, investor priorities, patient impact, and regulatory expectations—applied through a least‑burdensome, risk‑appropriate lens. In practice, this yields durable regulatory pathways that integrate into leadership planning, investor communications, and regulatory authority interactions.